The deal, made possible by strengthening relations between Venezuela and the United States, is expected to involve nearly $100 billion in investment to commercialize more than 65 billion barrels of P1 reserves in Venezuela.

CARACAS, Venezuela, Sept. 1, 2026 /PRNewswire/ — The United States Departments of State and War have reached an historic deal with North American Blue Energy Partners (NABEP) to significantly expand oil production in Venezuela. As part of the deal, NABEP will have operating control of the business, with the United States Government holding rights to a 35% stake in the company, alongside preferential access to 20% of the company’s production at cost.

President Donald J. Trump announced the agreement on Truth Social as “the biggest oil deal in world history” and is demonstrative of the U.S. and Venezuelan governments deepening collaboration in the Venezuelan oil sector, bringing jobs and fiscal stability for Venezuelans and lower prices at the pump for Americans.

“Venezuela is blessed with an abundance of natural resources, hardworking people and untapped potential,” said Alejandro Betancourt, CEO of NABEP. “This transaction will unleash that potential to the great benefit of both Venezuelans and Americans. We are grateful to President Donald J. Trump, Secretary Marco Rubio, Secretary Pete Hegseth, the United States Government, and to President Delcy Rodríguez and the Government of Venezuela, for their confidence in NABEP and their willingness to tackle this challenge with us. We look forward to pioneering a new and exciting path together.”

This new venture is expected to bring tens of millions of additional barrels of Venezuelan oil to the global marketplace, thousands of well-paid jobs to Venezuela, and billions in incremental investment and broader economic activity to drive growth in Venezuela’s recovering economy. Through the right to purchase 20% of the oil produced at cost, this venture will also ultimately deliver billions in savings for American consumers and secure a stable and growing strategic supply of oil in the Western Hemisphere. Through billions in purchases of oil infrastructure and equipment from U.S. suppliers, NABEP will also support thousands of manufacturing jobs in the United States.

Mr. Betancourt has been in the Venezuelan oil industry for more than 15 years with a consistent track record of success, most recently at the helm of NABEP, where he rapidly scaled the company’s production from approximately 18,000 barrels per day to more than 200,000 barrels per day through roughly $1 billion in company-funded investment, making it the country’s second-largest oil producer in just two years’ time. Today, the company directly employs over 5,000 people and supports over 10,000 contractor employees across Venezuela.

Following these transactions, NABEP now controls the rights to commercialize more than 65 billion barrels of P1 reserves in Venezuela. NABEP is seeking to rapidly expand its operations in Lake Maracaibo and the Orinoco Belt with the near-term goal of increasing production to more than 1 million barrels of oil per day.

As it was announced, the program will involve nearly $100 billion in investment to increase production capacity and oil and gas infrastructure in Venezuela and will generate more than $209 billion in tax revenue for the Venezuelan state.

In a statement posted to X immediately following the announcement, U.S. Secretary of State Marco Rubio said: “This deal is a huge win for both the American and Venezuelan people. It demonstrates how President Trump’s bold foreign policy is driving America First wins: securing stable reserves and low-cost oil in our Hemisphere and lowering gas prices here at home. For the Venezuelan people, this deal will bring nearly $100 billion in private investment, support thousands of high-paying jobs, and drive the reconstruction of Venezuela’s economy.”

About North American Blue Energy Partners
North American Blue Energy Partners (NABEP) is an independent oil exploration and production company operating in North and Latin America, with offices in Caracas, Maracaibo and Lechería. NABEP is committed to the responsible development of energy resources, the safety of its people, and the prosperity of the communities where it operates. www.nabep.net

Media contact
press@nabep.com

CHONGQING, China, Sept. 1, 2026 /PRNewswire/ — A news report from Xinhua Silk Road:

From “leading in scale” to “quality-led transformative growth”, the shift currently affecting China’s auto industry was brought under the spotlight during the recent 2026 Automotive New Quality Productive Force Development Forum.

Organized by China Economic Information Service and China Certification & Inspection Group, the event, held in Jiulongpo District of Chongqing, attracted a cohort of business representatives from the auto manufacturing and intelligent driving sectors.

As electric vehicle output and intelligent driving burgeon domestically, transformative growth instead of economy of scale remains a critical issue particularly for Chongqing, a leading auto- and motorcycle-producing city on its way to becoming a high-end player in the global value chain.

Regarding industry pain points such as high intelligent driving penetration yet low user trust, He Gang, vice president of Changan Automobile, stressed the significance of enhancing users’ sense of safety.

Via its all-weather dark-room laboratory and world models for smart driving, the Chongqing-based company is improving driving stability under extreme conditions and enabling advance detection of hazardous obstacles to build a three-pronged safety system.

He Liyang, president of Seres, outlined a set of principles centered on safety and performance that the company has consistently upheld in its development, saying “safety is the utmost luxury worth pursuing.”

To reduce homogeneous competition, Cao Li, senior vice president of Leapmotor, highlighted the importance of full-domain self-reliant research and manufacturing to navigate industry cycles.

With more than 65 percent of core parts developed and made by itself, the company, which owns 18 super factories, has built a closed-loop industrial cluster to keep quality, cost, and iteration efficiency fully under control.

In the face of industry controversies over powertrain technology routes, Wu Jian, a member of GAC Group’s strategy committee, said that traditional overseas powertrain technology routes have limitations in terms of intelligent adaptation.

Powertrains with Chinese characteristics can only be developed by delving into technologies that adapt to local scenarios and integrate well with vehicle intelligent systems, noted Wu, adding that after 20 years of independent R&D, the company now boasts three powertrain technology series for range-extended, plug-in hybrid, and hybrid electric vehicles.

As for “going global”, Wu Yongqiao, president of Bosch’s intelligent driving and control system division in China, said the company’s smart driving business is deeply involved in local innovation while aligning with overseas laws and regulations to facilitate the global expansion of Chinese auto companies.

To leverage technology for social good, Tang Guomei, deputy president of Sevnce Robotics, said the company focuses on resolving industry security dilemmas in special scenarios.

Addressing industry dilemmas such as insufficient cognitive generalization and causal reasoning in the evolution of intelligent driving systems, Yang Mu, CTO of Chongqing Afari Technology, a Chongqing-headquartered smart driving business, said the company is building a native intelligent driving base model by integrating large language models with intelligent driving models to strengthen smart vehicles’ capabilities in scene understanding, logical reasoning, and risk prediction.

Company to host a corporate update call Tuesday, September 1st at 8:00am ET

SYDNEY, Sept. 1, 2026 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the closing of its previously announced oversubscribed, tranched registered public offering (the “Offering”) generating approximately $40 million in upfront gross proceeds. Both clinical milestone-linked warrant tranches were priced at premiums to the $15.50 offering price, with exercise prices of $17.825 per ADS, a 15% premium, tied to the Company’s Stage IV triple-negative breast cancer (“TNBC”) data readout, and $19.375 per ADS, a 25% premium, tied to the Company’s HR+/HER2- breast cancer data readout. If all milestone-linked warrants are exercised in full, the Offering would provide Kazia with approximately $80 million in additional gross proceeds, for total potential gross proceeds of approximately $120 million.

The Offering consisted of (i) 2,580,000 American Depositary Shares (“ADSs”), each representing five hundred (500) ordinary shares of the Company, no par value per share, or in lieu of ADSs to certain investors, pre-funded warrants to purchase ADSs, (ii) accompanying Series A Warrants to purchase up to 2,243,478 ADSs (or pre-funded warrants in lieu thereof), exercisable immediately at a purchase price of $17.825 per ADS, expiring upon the earlier of 30 days following the Company’s Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or the five-year anniversary of issuance, and (iii) accompanying Series B Warrants to purchase up to 2,064,000 ADSs (or pre-funded warrants in lieu thereof), exercisable immediately at a purchase price of $19.375 per ADS, expiring upon the earlier of 30 days following the Company’s HR+/HER2- data readout, expected in the first half of 2028, or the five-year anniversary of issuance. All securities in the Offering were sold by Kazia.

The combined public offering price was $15.50 per ADS together with its accompanying Series A and Series B Warrants, and $15.4999 (equal to the combined public offering price per ADS and accompanying warrants less $0.0001) for each pre-funded warrant together with its accompanying Series A and Series B Warrants. Gross proceeds to Kazia at closing were approximately $40 million, before deducting underwriting discounts, commissions, and offering expenses.

The Offering included participation from new and existing institutional investors, including ADAR1 Capital Management, Columbia Threadneedle Investments, Lynx1 Capital Management, Marshall Wace, and Pointillist Family Office.

Leerink Partners and Guggenheim Securities acted as joint bookrunning managers, BTIG and Needham & Company acted as lead managers, and Laidlaw & Company (UK) Ltd. acted as co-manager for the Offering.

Kazia intends to use the net proceeds from the Offering primarily to fund clinical development of paxalisib, including ongoing and planned studies in triple-negative breast cancer, HR+/HER2- breast cancer, and pMMR colorectal cancer, as well as for working capital and general corporate purposes.

Corporate Update Call

Kazia Therapeutics will host a corporate update conference call on Tuesday, September 1, 2026, at 8:00am ET. A link to the webcast of the conference call will be available on the Kazia website at https://www.kaziatx.com/investors/news-and-events/ir-calendar or click here. The conference call can also be accessed by dialing 1-877-407-4018 (U.S.) or 1-201-689-8471 (international), using Conference ID: 13762519.

About Kazia Therapeutics

Kazia Therapeutics (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. The Company’s lead asset, paxalisib, is an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of over 15 clinical trials. A completed Phase 2/3 study in glioblastoma (GBM AGILE) was reported in 2024, and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. Additionally, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020 and for atypical teratoid/rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially first-in-class SETDB1 inhibitor program intended to restore immune signaling in tumors that have become resistant to immunotherapy, including checkpoint inhibitors. Both programs are currently in preclinical development. For more information, please visit www.kaziatx.com or follow us on X @KaziaTx.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements regarding the Offering and the potential gross proceeds therefrom, including the exercise of the Series A Warrants and Series B Warrants; the Company’s ability to achieve clinical milestones, including the Stage IV TNBC and HR+/HER2- data readouts that may trigger warrant exercise periods; the Company’s intended use of proceeds; and the Company’s plans for clinical development of paxalisib. Forward-looking statements are generally identified by words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “may,” “will,” “could,” “should,” “estimates,” “projects,” “potential,” and similar expressions. These forward-looking statements are based on management’s current expectations and assumptions as of the date of this press release and are subject to significant risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied.

Such risks and uncertainties include, but are not limited to: the Company’s ability to complete the Offering; the Company’s ability to achieve clinical milestones, including the Stage IV TNBC and HR+/HER2- data readouts that trigger warrant exercise periods; risks associated with the conduct of clinical trials and regulatory approvals; volatility in the price of the Company’s ADSs and warrants; general economic and market conditions; and the Company’s ability to maintain compliance with NASDAQ listing requirements.

For a more complete discussion of risks and uncertainties, please refer to the Company’s filings with the SEC, including the “Risk Factors” section of the Company’s most recent Annual Report on Form 20-F. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements are qualified in their entirety by this cautionary statement.

One fiber connector technology, from the optical engine to the box edge. Live connector demonstration at SEMICON Taiwan.

SAN JOSE, Calif., Sept. 1, 2026 /PRNewswire/ — Mixx Technologies, Inc., a US-based venture-backed deep-tech company building co-packaged optics for hyperscale AI infrastructure, today launched the SxC™ Connector, an optical connector for both the front plane and the backplane that terminates up to 24,576 fibers in a single rack unit. Mixx will hold live connector demonstrations at SEMICON Taiwan, booth #I2923, beginning September 2, 2026. 

Mixx’s first product to market is a fiber connector. The industry is moving toward co-packaged optics (CPO) in steps, through near-package optics, CPX, and similar socketed approaches. Each step needs more radix out of the box than existing connectors can deliver, and true CPO won’t arrive without it. The connector determines how much optical I/O a box can carry. This layer decides whether optics solves the inference challenge at rack scale or only demonstrates it on a bench.

Inference has changed what a scale-up network needs. Mixture-of-experts and agentic workloads require every node to reach every other node with the lowest latency, and that all-to-all connectivity comes down to radix, the number of endpoints a single node can reach. Higher radix reduces the switching layers a packet crosses. Each layer removed takes its switches, transceivers, and cables with it, which means lower latency, lower aggregate power, and fewer components in the failure chain. 

Scale-out runs on a mature pluggable transceiver ecosystem, and the opportunity in scale-up is to extend that ecosystem rather than replace it. But the arithmetic arrives at the connector. A 400T switch brings thousands of fibers out of a single box, and pluggable transceivers cannot support that density at the front panel. Once optics move inside the box, fiber becomes the next bottleneck, and existing connector families do not easily support the density this generation requires. The inference challenge also means replacing an electrical backplane with an optical one, a requirement the mature ecosystem was never built to meet. 

One connector technology, inside the box and outside it

The SxC™ Connector is the first product in the SxC™ connector family, the system-level connectivity layer of the HBxIO™ platform. It uses the same core connector technology Mixx deploys across the optical signal chain. Mixx builds the optical engine and the connector, so it can optimize the interface from the start rather than negotiating it across multiple vendors.

Each connector scales up to 64 fibers, supporting both SMF and PMF in the same form factor depending on customer requirements. The same connector serves the front plane and the backplane, mounted at the faceplate or seated in a bulkhead. The industry workhorse, the MPO, carries 16 in the configuration typically deployed for this application, and the newer, more compact VSFF also usually carries 16. The SxC™ form factor does not change with lane rate or optical power, so the connector supports current and next-generation rates without redesign. By ganging up sixteen connectors within a bulkhead for the backplane, Mixx can terminate 1,024 fibers in less than 800 square millimeters, which is the figure of merit for a connector: fibers per square millimeter. Radix resolves to fiber count, and fiber count resolves to density at the box edge.

Twenty-four bulkheads bring a single OCP rack unit to 24,576 fibers. That is 4x the fiber density of MMC-VSFF, the highest-density connector platform qualified for deployment today, and what previously required a four-rack-unit enclosure with MMC connectors now fits in a single rack unit. That density is what makes the next step in CPO integration possible. Advanced packaging and cooling technologies have scaled what can sit inside a box faster than the front panel has scaled what can come out of it, and a box of co-packaged optical engines is limited today by the fiber at the box edge, not by the silicon inside. Bringing the fiber out through the edge of the box at this density removes that limit and puts multi-petabit connectivity from a single box within reach. 

Mixx is a member of the Expanded Beam Optics Multi-Source Agreement (EBO MSA), the multi-source agreement standardizing expanded-beam optical connectors, and the first connector specification is now in development. Expanded beam is where the industry is heading, and Mixx is contributing to that work while building for deployments happening now. Mixx’s ferrule is glass rather than the plastic used in most connectors, which lets it handle the optical power levels that remote laser architectures and future multi-wavelength signals require. 

How the ferrule is made

Expanded-beam ferrules are conventionally assembled in series: starting with a V-groove substrate or molded plastic ferrules, individually placing fibers, dispensing epoxy, polishing, then actively aligning a lens before the assembly goes into a housing. That sequence limits fiber placement to a single array and reduces throughput and yield. Mixx forms the optical structures in a full wafer-scale integrated process using no exotic materials. The free-form optics, 3D waveguides, and 2D fiber holes are enabled by true wafer-scale processing, which allows fiber to be placed in a two-dimensional array to achieve high density and low loss.

Mixx is building an EBO connector that scales further than what is available today, so operators committing to optical infrastructure solutions now are committing to something that keeps scaling. Because the same core connector technology serves the optical engine, the external laser source (ELSFP), the backplane, and the front panel, volume aggregates across product lines instead of splitting across them. 

The ferrule was only half the problem. Cable assembly, the next step, has remained largely manual across the industry, and it is the constraint operators hit once ferrule supply is solved. Mixx is automating that step with robotic fiber assembly and automated visual inspection as part of the production pathway. The connector also supports passive fiber attach, drawing on years of pick-and-place optimization to remove the active-alignment step between lens and fiber that has historically limited yield and throughput.

“Every era of the data center has had a connector that carried it,” said Vivek Raghuraman, CEO of Mixx Technologies. “MPO carried one generation, and VSFF carried the next, and each one arrived because the network behind it had changed shape. Inference has changed the shape again. What Mixx has built is not a denser version of the last connector. It is one ferrule technology that terminates the signal chain at the package, at the laser, at the backplane, and at the front panel, so the connectivity problem gets solved once instead of four times.”

Demonstration

Mixx will show the connector at SEMICON Taiwan, booth #I2923, beginning September 2, 2026. The demonstration puts the hardware in visitors’ hands, not on a slide. Attendees can seat and unseat a fully populated bulkhead by hand, watch the link come up on each cycle, and see the ferrule that makes it possible. 

About Mixx Technologies

Mixx Technologies, Inc. is a venture-backed deep-tech company founded by the team that commercialized many zero-to-one silicon photonics products. The company is solving the data-movement bottleneck for AI compute infrastructure through its HBxIO™ platform, a multi-terabit, ultra-high-radix co-packaged optical interconnect architecture enabling cloud service providers to deploy large-scale AI inference at the speed and efficiency hyperscale demands. Headquartered in San Jose, California, with R&D operations in India and Taiwan. Visit mixxtech.io.

Media Contact:
Ramya Barna
Head of Marketing & Investor Relations
Mixx Technologies, Inc
Info@mixxtech.io

The next generation in skin resurfacing technology is available to Australian health care practitioners beginning 1 September 2026

LAVAL, QC, Sept. 1, 2026 /PRNewswire/ — Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics business, Solta Medical, today announced the availability of Fraxel FTX^® in Australia, expanding access to its latest skin resurfacing technology to Australian health care practitioners (HCPs) beginning 1 September 2026.

Building on more than 20 years of innovation in skin resurfacing, Fraxel FTX represents the next generation of the Fraxel^® platform. Designed to support treatment precision, workflow efficiency and patient comfort, Fraxel FTX brings together trusted technology with meaningful refinements for modern aesthetic practice.

“Fraxel FTX builds on the trusted technology of the Fraxel platform, combining proven performance with enhancements designed to support today’s aesthetic practices,” said Jiny Kim, Senior Vice President, Solta Medical, Bausch Health. “We are pleased to make this technology available in Australia and continue supporting practitioners with solutions designed to meet the evolving needs of their patients.”

Fraxel is one of the highly recognised treatments in skin resurfacing and may be used to address a range of common skin concerns, including the appearance of fine lines and wrinkles, lentigos and ephelides, acne scars and surgical scars, dyschromia including melasma, and actinic keratosis. With Fraxel FTX, Solta Medical continues to build on that clinical heritage with a system designed to support consistent treatment delivery across superficial and deeper skin layers.

“Fraxel has long been recognised by practitioners for its precision, versatility and clinical heritage,” said Alistair McKeon, General Manager, Solta, ANZ & SEA. “With Fraxel FTX, we are bringing Australian healthcare practitioners an updated platform that builds on that trusted foundation while supporting ease of use, treatment consistency and patient comfort in everyday practice.”

Key features and benefits of Fraxel FTX

• Two wavelengths, one intelligent approach: Fraxel FTX uses dual wavelengths to enable targeted treatment at different tissue depths. The 1927 nanometre wavelength targets the epidermal layer, while the 1550 nanometre wavelength penetrates into the deeper dermis while also treating the epidermis.
    
• Precision treatment delivery: As the tip moves over the skin, the laser treats a fraction of the skin at a time, creating a large number of microscopic treatment zones in a dot-like pattern. By leaving surrounding tissue intact, the system is designed to support rapid healing.
     
• Intelligent Optical Tracking™ with AccuTRAC^®: The patented optical system calculates hand motion during treatment to help support proper skin contact, dosimetry and uniform delivery, while making laser firing more efficient.
    
• Redesigned ergonomic handpiece: The handpiece features a 20% reduction in circumference and weight, and is designed to improve field of view, treatment precision and ease of handling.
    
• Integrated cooling designed for patient comfort: Cooling is routed through the handpiece and tip directly to the skin, with airflow directed at the treatment area.
    
• Refreshed treatment interface: The guided user interface is designed to facilitate treatment settings, total and estimated energy visibility, handpiece speed, and colour change between wavelengths.
    
• Modern console design: Fraxel FTX features an updated console with an integrated arm and cable assembly, in line with the Solta product family.

Fraxel FTX is a highly versatile and recognized treatment in aesthetics, designed to address five common skin concerns contributing to skin health: the appearance of fine lines and wrinkles, lentigos and ephelides, acne scars and surgical scars, dyschromia including melasma, and actinic keratosis.

Solta Medical supports health care practitioners with more than technology alone. In Australia and New Zealand, that includes clinical education, practical training and ongoing business support designed to help practitioners build confidence in treatment delivery and support long-term practice growth.

To learn more, visit soltamedical.com.au

THIS PRODUCT IS NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC. ALWAYS FOLLOW THE DIRECTIONS FOR USE. RESULTS MAY VARY.

About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our aesthetic business, Solta Medical, is a global leader in the aesthetics market, whose vision is to develop and support trusted aesthetic brands that provide value to our customers and patients. More information about Solta Medical can be found at www.solta.com. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn. 

Forward-looking Statements
This news release may contain forward-looking statements within the meaning of applicable securities laws, including the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words “will,” “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “subject to” and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health’s overall business, including those more fully described in Bausch Health’s most recent annual and quarterly reports and detailed from time to time in Bausch Health’s other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Fraxel^® is a trademark of Solta Medical, Inc. or its affiliates.

©2026 Solta Medical, Inc. or its affiliates

SEOUL, South Korea and BANGKOK, Sept. 1, 2026 /PRNewswire/ — LX Pantos Thailand has officially opened its newly renovated office at Lake Rajada Office Complex in Bangkok, following an opening ceremony held on August 7, 2026. The renovation reflects the company’s commitment to fostering a more collaborative workplace while supporting its long-term growth and strengthening its market presence in Thailand.

The office now spans the 17th and 19th floors, covering a total area of 883 square meters. The upgraded workplace is expected to improve operational efficiency and support the company’s expanding business in Thailand.

The opening ceremony was attended by Lee Jong Chan, CEO of LX Pantos Asia, and Yoon Jungyeon, Managing Director of LX Pantos Thailand, highlighting the strategic importance of the renovation as part of the company’s continued expansion in the local market.

Yoon Jungyeon, Managing Director of LX Pantos Thailand, said, “This renovation is designed to create a brighter and more open workspace that supports better communication, enhances employee satisfaction, and fosters a more positive working environment. We believe this new space will help strengthen our operations and support our long-term growth in Thailand.”

Employees responded positively to the upgraded workspace, highlighting the improved layout and meeting facilities.

This renovation marks an important step in strengthening LX Pantos Thailand’s workplace environment and supporting its long-term business development in one of Southeast Asia’s key logistics markets.

About LX Pantos Thailand

Established in 2003, LX Pantos Thailand is a leading provider of integrated logistics and supply chain solutions, offering services including international freight forwarding, warehousing, distribution, cross-border transportation, last-mile delivery, and installation services. As part of LX Pantos, a leading global logistics provider headquartered in Korea, the company delivers comprehensive logistics solutions through a worldwide network spanning more than 40 countries.